Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › neostigmine

neostigmine

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of neostigmine

31 trials tracked of neostigmine: 28 in phase 3 or 4 and 13 with published results. The most-cited published study has 380 citations.

31Trials tracked
28Phase 3 & 4
0Recruiting
13With published results
Phase distribution
Phase 4 19 Phase 3 9 Phase 1 1 Other / NA 2
  1. Phase 3 Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025) Completed · 380 cited
  2. Phase 3 Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960) Completed · 233 cited
  3. Phase 4 The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications Completed · 142 cited
  4. Phase 4 Neuromuscular Blockade on Shoulder Pain of Elderly Completed · 28 cited
  5. Phase 4 Deep Neuromuscular Block for Laparoscopic Surgery Completed · 25 cited
  6. Phase 4 Quality of Recovery After Reversal With Neostigmine or Sugammadex. Completed · 20 cited
Show 25 more trials
  1. Phase 4 Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery Completed · 18 cited
  2. Phase 4 Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular Completed · 14 cited
  3. Phase 3 Recovery of Diaphragmatic Function After Neuromuscular Blockade and Sugammadex Completed · 9 cited
  4. Phase 4 Sugammadex To IMprove Bowel Function Completed · 3 cited
  5. Phase 4 Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex Completed
  6. Phase 4 Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery Completed
  7. Phase 4 Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery Completed
  8. Phase 4 Effect of Neuromuscular Reversal With Sugammadex on Postoperative Recovery Profile Completed
  9. Phase 4 Study to Determine if Administration of Sugammadex Impacts Hospital Efficiency Completed
  10. Phase 4 Investigation of Sugammadex in Outpatient Urological Procedures Completed
  11. Phase 4 Effect of Neuromuscular Blockade and Reversal on Breathing Completed
  12. Phase 4 Optimizing Post-operative Recovery in Bariatric Patients With Obstructive Sleep Apnea Undergoing Outpatient Surgery: A Comparison of Sugammadex and Neostigmine Completed
  13. Phase 4 Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications Completed
  14. Phase 4 Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy Completed
  15. Phase 4 Impact of Anesthetic Choice (Sevoflurane Versus Desflurane) on Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block Completed
  16. Phase 4 Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage Completed
  17. Phase 3 Comparision of Different Dose of Neostigmine at Advanced Decurarization Completed
  18. Phase 3 Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981) Completed
  19. Phase 3 Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774) Completed
  20. Phase 3 Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101) Completed
  21. Phase 3 Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED) Completed
  22. Phase 3 Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699) Completed
  23. Phase 1 Epidural Neostigmine for Labor Pain Completed
  24. N/A Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals Completed
  25. N/A The Impacts of Surgical Visibility Through Deep Neuromuscular Blockade on Intraocular Pressure in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy Completed

Showing the 31 most-cited and recently-updated of 31 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Sugammadex reduces recovery time after surgery by 6.66 minutes compared to anticholinesterase agents
Gastroenterology Meta-analysis
Sugammadex reduces recovery time after surgery by 6.66 minutes compared to anticholinesterase agents Sugammadex May Help Patients Recover Faster After Surgery
This meta-analysis of 4,082 adult surgical patients compared sugammadex to anticholinesterase agents for neuromuscular blockade reversal. Th…
A review of surgical data suggests that sugammadex may lead to faster neuromuscular recovery and shorter recovery times compared to traditio…
Frontiers Oct 8, 2026
Sugammadex improves diaphragmatic excursion and reduces pulmonary complications in morbidly obese patients
Diabetes & Endocrinology RCT
Sugammadex improves diaphragmatic excursion and reduces pulmonary complications in morbidly obese patients Sugammadex Helps Obese Patients Breathe Easier
A randomized double-blind controlled trial in 104 morbidly obese patients compared sugammadex (2 mg/kg) with neostigmine+atropine.
This new research shows that a specific reversal drug helps morbidly obese patients breathe better and avoid lung issues after surgery.
Apr 14, 2026
Neostigmine infusion in septic shock linked to lower TNF-alpha and 28-day mortality in single-center RCT
Emergency Medicine RCT
Neostigmine infusion in septic shock linked to lower TNF-alpha and 28-day mortality in single-center RCT Neostigmine infusion linked to lower inflammation and mortality in septic shock trial
A single-center randomized controlled trial in adult ICU patients with septic shock compared a 5-day neostigmine infusion (0.2 mg/hr) to pla…
Septic shock patients receiving neostigmine showed lower inflammation, better organ scores, and fewer deaths compared to those on placebo in…
Apr 7, 2026